1. The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab.
- Author
-
Kuramochi H, Yamada T, Yoshida Y, Matsuda A, Kamiyama H, Kosugi C, Ishibashi K, Fukazawa A, Ihara K, Sonoda H, Yoshimatsu K, Yoshida H, Hasegawa S, Sakamoto K, Ishida H, and Koda K
- Subjects
- Aged, Antineoplastic Agents, Immunological administration & dosage, Bevacizumab administration & dosage, Colorectal Neoplasms pathology, Drug Combinations, Female, Humans, Male, Middle Aged, Pyrrolidines administration & dosage, Thymine administration & dosage, Trifluridine administration & dosage, Antineoplastic Agents, Immunological therapeutic use, Bevacizumab therapeutic use, Colorectal Neoplasms drug therapy, Lymphocytes pathology, Monocytes pathology, Neoplasm Metastasis drug therapy, Pyrrolidines therapeutic use, Thymine therapeutic use, Trifluridine therapeutic use
- Abstract
Background/aim: Our multicenter phase II TAS-CC3 study demonstrated favorable median progression-free survival (PFS) and overall survival (OS) of 32 metastatic colorectal cancer (mCRC) patients treated with TAS-102 + bevacizumab as 3
rd -line treatment., Patients and Methods: We investigated the predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS by a post-hoc analysis., Results: Receiver operating characteristic curve analyses of the 3 inflammation-based scores versus DC showed the best predictive performance for LMR, followed by NLR and PLR. The high-LMR group had a significantly higher DC rate than the low group (87.5 vs. 43.8%). The high-LMR group showed significantly longer survival than the low group (4.9 vs. 2.3 m for median PFS) (21.0 vs. 6.1 m for median OS)., Conclusion: The pre-treatment LMR is a valid predictive and prognostic biomarker for mCRC patients undergoing TAS-102 and bevacizumab treatment., (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF